GlaxoSmithKline PLC ADR Net Income
| GSK Stock | USD 58.82 0.19 0.32% |
As of the 10th of February, GlaxoSmithKline PLC retains the risk adjusted performance of 0.1916, and Market Risk Adjusted Performance of 0.6476. GlaxoSmithKline PLC technical analysis makes it possible for you to employ historical prices and volume momentum with the intention to determine a pattern that calculates the direction of the firm's future prices.
GlaxoSmithKline PLC Total Revenue |
|
Gross Profit | Profit Margin | Market Capitalization | Enterprise Value Revenue 3.1385 | Revenue |
| Last Reported | Projected for Next Year | ||
| Net Income | 5.6 B | 4.7 B | |
| Net Income Applicable To Common Shares | 5.7 B | 5.1 B | |
| Net Income From Continuing Ops | 2.7 B | 2.5 B | |
| Net Income Per Share | 1.41 | 1.48 | |
| Net Income Per E B T | 0.77 | 0.60 |
GlaxoSmithKline | Net Income | Build AI portfolio with GlaxoSmithKline Stock |
Historical Net Income data for GlaxoSmithKline PLC serves as a key indicator of operational performance and financial stability. Tracking changes in this metric over time helps investors spot emerging trends before they become obvious, providing an edge in assessing whether GlaxoSmithKline PLC ADR represents a compelling investment opportunity.
Latest GlaxoSmithKline PLC's Net Income Growth Pattern
Below is the plot of the Net Income of GlaxoSmithKline PLC ADR over the last few years. Net income is one of the most important fundamental items in finance. It plays a large role in GlaxoSmithKline PLC ADR financial statement analysis. It represents the amount of money remaining after all of GlaxoSmithKline PLC ADR operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue. It is GlaxoSmithKline PLC's Net Income historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in GlaxoSmithKline PLC's overall financial position and show how it may be relating to other accounts over time.
| View | Last Reported 5.59 B | 10 Years Trend |
|
Net Income |
| Timeline |
GlaxoSmithKline Net Income Regression Statistics
| Arithmetic Mean | 4,671,018,404 | |
| Geometric Mean | 3,595,744,613 | |
| Coefficient Of Variation | 70.85 | |
| Mean Deviation | 2,075,953,785 | |
| Median | 4,499,000,000 | |
| Standard Deviation | 3,309,319,426 | |
| Sample Variance | 10951595.1T | |
| Range | 14.6B | |
| R-Value | 0.24 | |
| Mean Square Error | 11004012.1T | |
| R-Squared | 0.06 | |
| Significance | 0.35 | |
| Slope | 157,845,017 | |
| Total Sum of Squares | 175225521T |
GlaxoSmithKline Net Income History
Other Fundumenentals of GlaxoSmithKline PLC ADR
| Net Income Applicable To Common Shares | ||
| Net Income From Continuing Ops | ||
| Net Income Per Share | ||
| Net Income Per E B T |
GlaxoSmithKline PLC Net Income component correlations
GlaxoSmithKline Net Income Driver Correlations
Understanding the fundamental principles of building solid financial models for GlaxoSmithKline PLC is extremely important. It helps to project a fair market value of GlaxoSmithKline Stock properly, considering its historical fundamentals such as Net Income. Since GlaxoSmithKline PLC's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of GlaxoSmithKline PLC's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of GlaxoSmithKline PLC's interrelated accounts and indicators.
Click cells to compare fundamentals
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of GlaxoSmithKline PLC. Market participants price GlaxoSmithKline higher when confident in its future expansion prospects. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive GlaxoSmithKline PLC assessment requires weighing all these inputs, though not all factors influence outcomes equally.
Quarterly Earnings Growth 0.551 | Dividend Share 0.66 | Earnings Share 3.78 | Revenue Per Share | Quarterly Revenue Growth 0.062 |
Investors evaluate GlaxoSmithKline PLC ADR using market value (trading price) and book value (balance sheet equity), each telling a different story. Calculating GlaxoSmithKline PLC's intrinsic value - the estimated true worth - helps identify when the stock trades at a discount or premium to fair value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. External factors like market trends, sector rotation, and investor psychology can cause GlaxoSmithKline PLC's market price to deviate significantly from intrinsic value.
Please note, there is a significant difference between GlaxoSmithKline PLC's value and its price as these two are different measures arrived at by different means. Investors typically determine if GlaxoSmithKline PLC is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. Conversely, GlaxoSmithKline PLC's market price signifies the transaction level at which participants voluntarily complete trades.
GlaxoSmithKline PLC 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to GlaxoSmithKline PLC's stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of GlaxoSmithKline PLC.
| 11/12/2025 |
| 02/10/2026 |
If you would invest 0.00 in GlaxoSmithKline PLC on November 12, 2025 and sell it all today you would earn a total of 0.00 from holding GlaxoSmithKline PLC ADR or generate 0.0% return on investment in GlaxoSmithKline PLC over 90 days. GlaxoSmithKline PLC is related to or competes with Bristol Myers, Sanofi ADR, HCA Holdings, Cigna Corp, CVS Health, McKesson, and Elevance Health. GSK plc, together with its subsidiaries, engages in the creation, discovery, development, manufacture, and marketing of ... More
GlaxoSmithKline PLC Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure GlaxoSmithKline PLC's stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess GlaxoSmithKline PLC ADR upside and downside potential and time the market with a certain degree of confidence.
| Downside Deviation | 1.3 | |||
| Information Ratio | 0.1757 | |||
| Maximum Drawdown | 9.32 | |||
| Value At Risk | (2.03) | |||
| Potential Upside | 2.41 |
GlaxoSmithKline PLC Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for GlaxoSmithKline PLC's investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as GlaxoSmithKline PLC's standard deviation. In reality, there are many statistical measures that can use GlaxoSmithKline PLC historical prices to predict the future GlaxoSmithKline PLC's volatility.| Risk Adjusted Performance | 0.1916 | |||
| Jensen Alpha | 0.3188 | |||
| Total Risk Alpha | 0.1996 | |||
| Sortino Ratio | 0.2188 | |||
| Treynor Ratio | 0.6376 |
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of GlaxoSmithKline PLC's price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
GlaxoSmithKline PLC February 10, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | 0.1916 | |||
| Market Risk Adjusted Performance | 0.6476 | |||
| Mean Deviation | 1.2 | |||
| Semi Deviation | 0.9323 | |||
| Downside Deviation | 1.3 | |||
| Coefficient Of Variation | 429.06 | |||
| Standard Deviation | 1.61 | |||
| Variance | 2.61 | |||
| Information Ratio | 0.1757 | |||
| Jensen Alpha | 0.3188 | |||
| Total Risk Alpha | 0.1996 | |||
| Sortino Ratio | 0.2188 | |||
| Treynor Ratio | 0.6376 | |||
| Maximum Drawdown | 9.32 | |||
| Value At Risk | (2.03) | |||
| Potential Upside | 2.41 | |||
| Downside Variance | 1.68 | |||
| Semi Variance | 0.8691 | |||
| Expected Short fall | (1.41) | |||
| Skewness | 1.07 | |||
| Kurtosis | 4.13 |
GlaxoSmithKline PLC ADR Backtested Returns
GlaxoSmithKline PLC appears to be very steady, given 3 months investment horizon. GlaxoSmithKline PLC ADR holds Efficiency (Sharpe) Ratio of 0.22, which attests that the entity had a 0.22 % return per unit of standard deviation over the last 3 months. We have found twenty-eight technical indicators for GlaxoSmithKline PLC ADR, which you can use to evaluate the volatility of the firm. Please utilize GlaxoSmithKline PLC's market risk adjusted performance of 0.6476, and Risk Adjusted Performance of 0.1916 to validate if our risk estimates are consistent with your expectations. On a scale of 0 to 100, GlaxoSmithKline PLC holds a performance score of 17. The company retains a Market Volatility (i.e., Beta) of 0.57, which attests to possible diversification benefits within a given portfolio. As returns on the market increase, GlaxoSmithKline PLC's returns are expected to increase less than the market. However, during the bear market, the loss of holding GlaxoSmithKline PLC is expected to be smaller as well. Please check GlaxoSmithKline PLC's coefficient of variation, semi variance, period momentum indicator, as well as the relationship between the treynor ratio and daily balance of power , to make a quick decision on whether GlaxoSmithKline PLC's current trending patterns will revert.
Auto-correlation | 0.36 |
Below average predictability
GlaxoSmithKline PLC ADR has below average predictability. Overlapping area represents the amount of predictability between GlaxoSmithKline PLC time series from 12th of November 2025 to 27th of December 2025 and 27th of December 2025 to 10th of February 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of GlaxoSmithKline PLC ADR price movement. The serial correlation of 0.36 indicates that just about 36.0% of current GlaxoSmithKline PLC price fluctuation can be explain by its past prices.
| Correlation Coefficient | 0.36 | |
| Spearman Rank Test | 0.42 | |
| Residual Average | 0.0 | |
| Price Variance | 12.61 |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
GlaxoSmithKline Accumulated Other Comprehensive Income
Accumulated Other Comprehensive Income |
|
Based on the recorded statements, GlaxoSmithKline PLC ADR reported net income of 5.59 B. This is much higher than that of the Pharmaceuticals sector and significantly higher than that of the Health Care industry. The net income for all United States stocks is significantly lower than that of the firm.
GlaxoSmithKline Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses GlaxoSmithKline PLC's direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of GlaxoSmithKline PLC could also be used in its relative valuation, which is a method of valuing GlaxoSmithKline PLC by comparing valuation metrics of similar companies.GlaxoSmithKline PLC is currently under evaluation in net income category among its peers.
GlaxoSmithKline PLC ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, GlaxoSmithKline PLC's sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to GlaxoSmithKline PLC's managers, analysts, and investors.Environmental | Governance | Social |
GlaxoSmithKline PLC Institutional Holders
Institutional Holdings refers to the ownership stake in GlaxoSmithKline PLC that is held by large financial organizations, pension funds or endowments. Institutions may hold large blocks of GlaxoSmithKline PLC's outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing GlaxoSmithKline PLC's value.| Shares | Ubs Group Ag | 2025-06-30 | 5.2 M | Morgan Stanley - Brokerage Accounts | 2025-06-30 | 5.2 M | Bank Of America Corp | 2025-06-30 | 5.1 M | Hotchkis & Wiley Capital Management Llc | 2025-06-30 | 4.6 M | Manufacturers Life Insurance Co | 2025-06-30 | 4.2 M | Equity Investment Corp | 2025-06-30 | 4.2 M | Federated Hermes Inc | 2025-06-30 | 3.6 M | Envestnet Asset Management Inc | 2025-06-30 | 3.5 M | Alyeska Investment Group, L.p. | 2025-06-30 | 3.2 M | Dodge & Cox | 2025-06-30 | 78.8 M | Fmr Inc | 2025-06-30 | 61 M |
GlaxoSmithKline Fundamentals
| Return On Equity | 0.43 | ||||
| Return On Asset | 0.0978 | ||||
| Profit Margin | 0.17 % | ||||
| Operating Margin | 0.17 % | ||||
| Current Valuation | 139.51 B | ||||
| Shares Outstanding | 2.01 B | ||||
| Shares Owned By Insiders | 0.06 % | ||||
| Shares Owned By Institutions | 19.24 % | ||||
| Number Of Shares Shorted | 17.55 M | ||||
| Price To Earning | 11.80 X | ||||
| Price To Book | 5.31 X | ||||
| Price To Sales | 3.62 X | ||||
| Revenue | 31.95 B | ||||
| Gross Profit | 23.72 B | ||||
| EBITDA | 11.62 B | ||||
| Net Income | 5.59 B | ||||
| Cash And Equivalents | 2.75 B | ||||
| Cash Per Share | 0.32 X | ||||
| Total Debt | 17.69 B | ||||
| Debt To Equity | 0.98 % | ||||
| Current Ratio | 1.43 X | ||||
| Book Value Per Share | 5.55 X | ||||
| Cash Flow From Operations | 7.14 B | ||||
| Short Ratio | 4.97 X | ||||
| Earnings Per Share | 3.78 X | ||||
| Price To Earnings To Growth | 0.38 X | ||||
| Target Price | 56.06 | ||||
| Number Of Employees | 68.63 K | ||||
| Beta | 0.27 | ||||
| Market Capitalization | 118.41 B | ||||
| Total Asset | 61.01 B | ||||
| Retained Earnings | 10.19 B | ||||
| Working Capital | (4.7 B) | ||||
| Current Asset | 16.59 B | ||||
| Current Liabilities | 13.42 B | ||||
| Annual Yield | 0.03 % | ||||
| Five Year Return | 5.32 % | ||||
| Net Asset | 61.01 B | ||||
| Last Dividend Paid | 0.66 |
About GlaxoSmithKline PLC Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze GlaxoSmithKline PLC ADR's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of GlaxoSmithKline PLC using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of GlaxoSmithKline PLC ADR based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Prophet is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ProphetCheck out You can also try the Piotroski F Score module to get Piotroski F Score based on the binary analysis strategy of nine different fundamentals.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of GlaxoSmithKline PLC. Market participants price GlaxoSmithKline higher when confident in its future expansion prospects. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive GlaxoSmithKline PLC assessment requires weighing all these inputs, though not all factors influence outcomes equally.
Quarterly Earnings Growth 0.551 | Dividend Share 0.66 | Earnings Share 3.78 | Revenue Per Share | Quarterly Revenue Growth 0.062 |
Investors evaluate GlaxoSmithKline PLC ADR using market value (trading price) and book value (balance sheet equity), each telling a different story. Calculating GlaxoSmithKline PLC's intrinsic value - the estimated true worth - helps identify when the stock trades at a discount or premium to fair value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. External factors like market trends, sector rotation, and investor psychology can cause GlaxoSmithKline PLC's market price to deviate significantly from intrinsic value.
Please note, there is a significant difference between GlaxoSmithKline PLC's value and its price as these two are different measures arrived at by different means. Investors typically determine if GlaxoSmithKline PLC is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. Conversely, GlaxoSmithKline PLC's market price signifies the transaction level at which participants voluntarily complete trades.